Drug Trial Radar · NCT07624201
Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Jun 1, 2028
Study completion Jun 1, 2029
Sponsor
- Lead sponsor
- Harbin Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Fourth Affiliated Hospital of China Medical University; Jilin Provincial Tumor Hospital; Tianjin Medical University Second Hospital; First Hospital of China Medical University
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of neoadjuvant trastuzumab rezetecan combined with adebrelimab for the treatment of HER2-positive muscle-invasive bladder cancer.
Conditions
- Muscle-Invasive Bladder Cancer (MIBC)
Interventions
Trastuzumab Rezetecan Combined with AdebelizumabDrug
Trastuzumab Rezetecan 3.2 mg/kg, Q3W, in combination with Adebrelimab 1200 mg, Q3W, for a total of 3 cycles. Subjects will undergo preoperative imaging and surgical eligibility assessment at 3-4 weeks after the last dose of neoadjuvant therapy. Those who meet the surgical criteria will receive either transurethral resection or radical resection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete ResponseTime frame: Assessed post-surgery (radical cystectomy or TURBT) on resected tumor specimens after neoadjuvant therapy. Measured postoperatively, up to approximately 4 months after treatment start.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Harbin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.